nach oben

Erschienen in:

01.09.2015 | Original Article

Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma

Comparison of ILROG IS-RT and the GHSG IF-RT

verfasst von: Jan Kriz, M.D., Max Spickermann, Philipp Lehrich, Heinz Schmidberger, M.D., PhD., Gabriele Reinartz, M.D., Hans Eich, M.D., PhD., Uwe Haverkamp, M.D., PhD.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The present study addresses the role of intensity-modulated radiotherapy (IMRT) in contrast to standard RT (APPA) for patients with Hodgkin’s lymphoma (HL) with a focus on deep inspiration breath-hold (DIBH) technique and a comparison between the International Lymphoma Radiation Oncology Group (ILROG) Involved Site Radiotherapy (IS-RT) versus the German Hodgkin Study Group (GHSG) Involved Field Radiotherapy (IF-RT).

Methods

APPA treatment and 2 IMRT plans were compared for 11 patients with HL. Furthermore, treatment with DIBH versus free breathing (FB) and two different treatment volumes, i.e. IF-RT versus IS-RT, were compared. IMRT was planned as a sliding-window technique with 5 and 7 beam angles. For each patient 12 different treatment plans were calculated (132 plans). Following organs at risk (OAR) were analysed: lung, heart, spinal cord, oesophagus, female breast and skin. Comparisons of the different values with regard to dose–volume histograms (DVH), conformity and homogeneity indices were made.

Results

IS-RT reduces treatment volumes. With respect to the planning target volume (PTV), IMRT achieves better conformity but the same homogeneity. Regarding the D_mean for the lung, IMRT shows increased doses, while RT in DIBH reduces doses. The IMRT shows improved values for D_max concerning the spinal cord, whereas the APPA shows an improved D_mean of the lung and the female breast.

Conclusion

IS-RT reduces treatment volumes. Intensity-modulated radiotherapy shows advantages in the conformity. Treatment in DIBH also reduces the dose applied to the lungs and the heart.

Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148CrossRefPubMed

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED (2010) Quantitative Analyses of Normal Tissue Effects in the Clinic. Int J Radiat Oncol Biol Phys 76:1–160CrossRef

Burman C, Kutcher GJ, Emami B, Goitein M (1991) Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21:123–135CrossRefPubMed

Chera BS, Rodriguez C, Morris CG et al (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173–1180CrossRefPubMed

Darby SC, Cutter DJ, Boerma M et al (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656–665PubMedCentralCrossRefPubMed

De Sanctis V, Bolzan C, D’Arienzo M, Bracci S, Fanelli A, Cox MC et al (2012) Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol 7:129-717X-7-129PubMedCentralCrossRefPubMed

Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410CrossRefPubMed

Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206CrossRefPubMed

Eich HT, Kriz J, Schmidberger H et al (2013) The German evidence-based guidelines for Hodgkin’s lymphoma. Aspects for radiation oncologists. Strahlenther Onkol 189:445–447CrossRefPubMed

10.

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122CrossRefPubMed

11.

Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608CrossRefPubMed

12.

Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed

13.

Fiandra C, Filippi AR, Catuzzo P et al (2012) Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186PubMedCentralCrossRefPubMed

14.

Gagliardi G, Constine LS, Moiseenko V et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85CrossRef

15.

Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D (2006) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218–226CrossRefPubMed

16.

Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277CrossRefPubMed

17.

Goodman KA, Toner S, Hunt M et al (2005) Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62:198–206CrossRefPubMed

18.

Haverkamp U, Norkus D, Kriz J et al (2014) Optimization by visualization of indices. Strahlenther Onkol 190:1053–1059CrossRefPubMed

19.

ICRU Report No. (2010) 83 International Commission on Radiation Units and Measurements—Prescribing, Recording, and Reporting Intensity–Modulated Photon-Beam Therapy. ICRU 83

20.

Koeck J, Abo-Madyan Y, Eich HT et al (2012) Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin’s disease. Strahlenther Onkol 188:653–659CrossRefPubMed

21.

Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83:268–276CrossRefPubMed

22.

Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol 190:864–866, 868–871

23.

Lu NN, Li YX, Wu RY et al (2012) Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin’s lymphoma with mediastinal involvement. Int J Radiat Oncol Biol Phys 84:210–216CrossRefPubMed

24.

Milano MT, Constine LS, Okunieff P (2007) Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 17:131–140CrossRefPubMed

25.

Ng AK, Kenney LB, Gilbert ES, Travis LB (2010) Secondary malignancies across the age spectrum. Semin Radiat Oncol 20:67–78CrossRefPubMed

26.

Nieder C, Schill S, Kneschaurek P, Molls M (2007) Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 82:301–307CrossRefPubMed

27.

Nilsson G, Holmberg L, Garmo H et al (2012) Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380–386CrossRefPubMed

28.

Paumier A, Ghalibafian M, Gilmore J et al (2012) Dosimetric benefit of intensity modulated radiotherapy combined with deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s Lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527CrossRefPubMed

29.

Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma—field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862CrossRefPubMed

30.

Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supradiaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586CrossRefPubMed

31.

Wu VWC, Kwong DLW, Sham JST (2004) Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Radiother Oncol 71:201–206CrossRefPubMed

Titel: Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma
Comparison of ILROG IS-RT and the GHSG IF-RT
verfasst von: Jan Kriz, M.D.
Max Spickermann
Philipp Lehrich
Heinz Schmidberger, M.D., PhD.
Gabriele Reinartz, M.D.
Hans Eich, M.D., PhD.
Uwe Haverkamp, M.D., PhD.
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0839-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma

Comparison of ILROG IS-RT and the GHSG IF-RT